FDA approves tocilizumab to treat rheumatoid arthritis

Thompson, Cheryl A.
February 2010
American Journal of Health-System Pharmacy;2/15/2010, Vol. 67 Issue 4, p254
Academic Journal
The article offers information on the U.S. Food and Drug Administration (FDA) approving the of tocilizumab drug. It reports that the drug treats rheumatoid arthritis and is marketed by Genentech Inc. which made the announcement on January 8. The company said that the drug is first monoclonal antibody designed specifically inhibit the activity of interleukin-6 that is produced in the joints by the disease.


Related Articles

  • Genentech wins FDA approval for rheumatoid arthritis drug.  // PharmaWatch: Biotechnology;Feb2010, Vol. 9 Issue 2, p12 

    The article reports on the approval of Food and Drug Administration of Genentech Inc.'s Actemra that is use to treat patients with active rheumatoid arthritis (RA) in the U.S. Actemra is the first interleukin-6 receptor inhibiting monoclonal antibody that can either be used alone or with...

  • Genentech's Actemra Wins FDA Approval in Rheumatoid Arthritis. Young, Donna // BioWorld Today;1/12/2010, Vol. 21 Issue 7, p1 

    The article reports that the U.S. Food & Drug Administration (FDA) approved the use of Actemra (tocilizumab), from Genentech Inc., as a once-monthly intravenous treatment for moderate to severe active rheumatoid arthritis in adults. Actemra is the first interleukin-6 receptor-inhibiting...

  • Simponi.  // Formulary;Jun2009, Vol. 44 Issue 6, p163 

    The article offers information on biologic Simponi, an anti-tumor necrosis factor (TNF)-alpha monoclonal antibody. The drug, which received approval from the U.S., Food and Drug Administration on April 24, 2009, is useful in the treatment of rheumatoid arthritis, psoriatic arthritis, and...

  • Genentech Reports 2nd Positive Study of ACTEMRA(r) Given by Subcutaneous Injection to Patients with Rheumatoid Arthritis.  // Biomedical Market Newsletter;8/7/2012, Vol. 21, p1 

    The article informs that Genentech Inc. has released the positive results from the clinical trial of ACTEMRA for the treatment of rheumatoid arthritis. It further informs that the company will be submitting the results to the U.S. Food and Drug Administration for gaining approval for ACTEMRA. It...

  • Genentech/Biogen Idec: Rituxan further expands its options.  // PharmaWatch: Monthly Review;Apr2006, Vol. 5 Issue 4, p29 

    The article reports that the U.S. Food and Drug Administration approved the drug Rituxan from Genentech Inc. and Biogen Idec Inc. to help treat rheumatoid arthritis (RA). The approval allows the companies to market Rituxan to be used with methotrexate for the treatment of signs and symptoms of...

  • FDA Actions. Elliott, William T. // Clinical Cardiology Alert;Jun2009 Pharmacology Watch, p2 

    The article presents an update on U.S. Food and Drug Administration (FDA) actions in 2009. A morning after pill called Plan B from Duramed Pharmaceuticals will be available to women age 17 and older without a prescription following a court order directing the FDA to evaluate clinical data to...

  • Genentech's Gazyva Gets Green Light In Chronic Lymphocytic Leukemia. Powers, Marie // BioWorld Today;11/4/2013, Vol. 24 Issue 212, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved and designated Gazyva (obinutuzumab) by Genentech Inc. as breakthrough therapy for chronic lymphocytic leukemia (CLL). It states that Gazyva is a monoclonal antibody that targets CD20 protein of malignant B cells....

  • FDA Grants Genentech's Pertuzumab Priority Review for Previously Untreated HER2- Positive Metastatic Breast Cancer.  // Biomedical Market Newsletter;2/7/2012, Vol. 21, p1 

    The article reports on an announcement made by Genentech Inc. regarding the acceptance of company's Biologics License Application for pertuzumab by the U.S. Food and Drug Administration (FDA). FDA has granted a priority review for the drug because of the need for new medicines for the treatment...

  • Tocilizumab. Scheinecker, Clemens; Smolen, Josef; Yasothan, Uma; Stoll, Jeffrey; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Apr2009, Vol. 8 Issue 4, p273 

    In January 2009, tocilizumab (RoActemra; Chugai/Roche), a humanized monoclonal antibody that binds to the interleukin-6 receptor, was granted marketing authorization by the European Commission for the treatment of moderate to severe rheumatoid arthritis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics